Aclaris Therapeutics, Inc.

NasdaqGS ACRS

Aclaris Therapeutics, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -138.00%

Aclaris Therapeutics, Inc. EBT Margin is -138.00% for the Trailing 12 Months (TTM) ending September 30, 2024, a 74.20% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Aclaris Therapeutics, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -534.83%, a -53.13% change year over year.
Aclaris Therapeutics, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -349.26%, a 70.81% change year over year.
Aclaris Therapeutics, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -1,196.49%, a -26.47% change year over year.
Aclaris Therapeutics, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -946.04%, a 1.30% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

NasdaqGS: ACRS

Aclaris Therapeutics, Inc.

CEO	Dr. Neal S. Walker D.O., M.D.
IPO Date	Oct. 6, 2015
Location	United States
Headquarters	640 Lee Road
Employees	86
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Key trends

Past 5 years